Fred Saad, CQ, MD, FRCS, FCAHS

Fred Saad, CQ, MD, FRCS, FCAHS, is the director of Prostate Cancer Research at Montreal Cancer Institute, Centre Hospitalier de l’Université de Montréal. He is also a full professor in the Department of Surgery at Université de Montréal and a uro-oncologist in the Urology Department at the University of Montreal Health Center.

Articles

Dr Saad on the Efficacy of Darolutamide Plus ADT In Low and High Volume mHSPC

February 14th 2025

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the efficacy and safety of darolutamide plus ADT in mHSPC according to disease volume.

Dr Saad on the Safety Profile of Darolutamide Plus ADT in mHSPC

October 25th 2024

Fred Saad, CQ, MD, FRCS, FCAHS, discusses the safety findings from the phase 3 ARANOTE trial investigating darolutamide plus ADT in patients with mHSPC.

Dr. Saad on the Efficacy of First-Line Olaparib Plus Abiraterone in mCRPC

February 17th 2022

Fred Saad, MD, FRCS, discusses the efficacy of olaparib plus abiraterone acetate as first-line treatment in metastatic castration-resistant prostate cancer.

Dr. Saad on Results of Radium-223 Trial in Prostate Cancer

March 2nd 2017

Fred Saad, MD, professor and chief of Urology, director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses results of a trial that investigated early use of radium-223 dichloride (Xofigo) in patients with asymptomatic metastatic castration-resistant prostate cancer.

Dr. Saad on Apalutamide Combination for Castration-Resistant Prostate Cancer

February 23rd 2017

Fred Saad, MD, University of Montreal Hospital Centers, discusses the safety and efficacy of the apalutamide combination for patients with metastatic castration-resistant prostate cancer.

Dr. Saad on Radium-223 for Prostate Cancer

February 22nd 2017

Fred Saad, MD, professor and chief of Urology, Director of Genitourinary Oncology at the University of Montreal Hospital Centers, discusses radium-223 dichloride (Xofigo) for patients with prostate cancer.

Dr. Saad on Recent Updates in Active Surveillance in Prostate Cancer

February 20th 2017

Fred Saad, MD, professor and chairman of Urology, director of Genitourinary Oncology, the University of Montreal Hospital Centers, discusses recent updates in active surveillance for patients with prostate cancer.

Dr. Saad on Patients With mCRPC Eligible for 6-Doses of Radium-223

July 8th 2016

Fred Saad, MD, professor and chairman of Urology, director of GU Oncology, the University of Montreal Hospital Centers, discusses results of an analysis that examined which patients with metastatic castration-resistant prostate cancer are able to receive the recommended 6-doses of radium-223 dichloride (Xofigo).

Dr. Saad on Expanded Access Program With Radium-223

February 23rd 2016

Fred Saad, MD, FRCSC, principal scientist, full professor, Department of Surgery, chair in Prostate Cancer Research, Université de Montréal, medical director, Interdisciplinary Urologic Oncology Group, head, Urologic Oncology, CHUM, discusses the expanded access program (EAP) of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

Dr. Saad on Next Steps for Radium-223 in mCRPC

October 26th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses expected next steps associated with radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer.

Dr. Saad on Radium-223 in Patients with mCRPC

June 29th 2015

Fred Saad, MD, FRCS, professor, Department of Surgery, University of Montreal, discusses the use of radium-223 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

x